close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyte Corporation

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte Corporation
Via Business Wire
Tickers INCY
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
From Incyte Corporation
Via Business Wire
Tickers INCY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today